Keryx Biopharmaceuticals Inc. (KERX)
-NasdaqCM | Prev Close: | 8.04 |
|---|
| Open: | N/A |
|---|
| Bid: | 7.58 x 2000 |
|---|
| Ask: | 8.74 x 100 |
|---|
| 1y Target Est: | 12.44 |
|---|
| Beta: | 3.43 |
|---|
| Next Earnings Date: | 5-Aug-13 |
|---|
| Day's Range: | N/A - N/A |
|---|
| 52wk Range: | 1.55 - 9.98 |
|---|
| Volume: | 0 |
|---|
| Avg Vol (3m): | 2,982,590 |
|---|
| Market Cap: | 657.01M |
|---|
| P/E (ttm): | N/A |
|---|
| EPS (ttm): | -0.21 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- Is Keryx Biopharmaceuticals Burning Too Much Cash?at Motley Fool(Sun, May 19)
- KERYX BIOPHARMACEUTICALS INC FinancialsEDGAR Online Financials(Wed, May 15)
- Earnings Volatility Drives These Stocks in a New Directionat Wall St. Cheat Sheet(Sun, May 12)
- Weekly Stock Watch - Week Of May 13, 2013at Seeking Alpha(Sat, May 11)
- Short Interest Increases 10% For KERXat TheStreet(Fri, May 10)
- Keryx Biopharmaceutical's CEO Discusses Q1 2013 Results - Earnings Call Transcriptat Seeking Alpha(Wed, May 8)
- 3 Key Takeaways From Keryx's Earnings Reportat Motley Fool(Wed, May 8)
- KERYX BIOPHARMACEUTICALS INC Files SEC form 10-Q, Quarterly ReportEDGAR Online(Wed, May 8)
- Keryx: A Small Biotech With Many Catalystsat Seeking Alpha(Wed, May 8)
- Keryx Biopharmaceuticals, Inc. Earnings Call scheduled for 8:30 am ET todayCCBN(Wed, May 8)
- Keryx Biopharmaceuticals Earnings: Here’s Why Shares are Up Nowat Wall St. Cheat Sheet(Tue, May 7)
- Keryx Biopharmaceuticals, Inc. Announces First Quarter 2013 Financial ResultsPR Newswire(Tue, May 7)
- Whisper Number Impact: Earnings Preview For Keryx Biopharmaceuticalsat Seeking Alpha(Tue, May 7)
- KERYX BIOPHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial ConditionEDGAR Online(Tue, May 7)
- Keryx Biopharmaceuticals, Inc. To Host Conference Call on First Quarter 2013 Financial ResultsPR Newswire(Mon, May 6)
Key Statistics
| Forward P/E (1 yr): | 100.50 |
|---|
| P/S (ttm): | 93.86 |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(Dec-13)
: | -0.32 |
|---|
| Quarterly EPS Est
(Jun-13)
: | -0.10 |
|---|
| Mean Recommendation*: | 1.6 |
|---|
| PEG Ratio (5 yr expected): | -0.83 |
|---|
Business Summary
Keryx Biopharmaceuticals, Inc., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of pharmaceutical products for the treatment of renal disease in the United States.
View More